Vaishali Pharma Limited (NSE:VAISHALI)
India
· Delayed Price · Currency is INR 11.60
+0.06 (0.52%)
Jun 30, 2025, 3:29 PM IST
Vaishali Pharma Revenue
In the fiscal year ending March 31, 2025, Vaishali Pharma had annual revenue of 1.02B INR with 18.49% growth. Vaishali Pharma had revenue of 332.50M in the quarter ending March 31, 2025, with 2.64% growth.
Revenue
1.02B
Revenue Growth
+18.49%
P/S Ratio
1.37
Revenue / Employee
37.86M
Employees
27
Market Cap
1.40B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.02B | 159.51M | 18.49% |
| Mar 31, 2024 | 862.80M | 166.17M | 23.85% |
| Mar 31, 2023 | 696.63M | -61.58M | -8.12% |
| Mar 31, 2022 | 758.21M | 220.47M | 41.00% |
| Mar 31, 2021 | 537.74M | -63.12M | -10.50% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 525.78B |
| Divi's Laboratories | 93.60B |
| Cipla | 272.67B |
| Apollo Hospitals Enterprise | 217.94B |
| Zydus Lifesciences | 232.42B |
| Mankind Pharma | 122.07B |
| Aurobindo Pharma | 317.24B |
| Fortis Healthcare | 77.83B |
Vaishali Pharma News
- 9 months ago - Vaishali Pharma shares surge 3% after company plans on ambitious growth strategy - Business Upturn
- 9 months ago - Vaishali Pharma to explore merger and acquisition strategy in upcoming board meeting on October 3 - Business Upturn
- 10 months ago - Vaishali Pharma Ltd (NSE:VAISHALI) Q3 2024 Earnings Call Transcript Highlights: Strong ... - GuruFocus